Roche and Hansoh Strike ADC Strategic Collaboration and License Deal Worth Over $15.5 Billion

Hansoh Pharmaceutical and Roche entered a new ADC strategic collaboration and license agreement on October 19. Hansoh will receive a $400 million upfront payment and a $110 million one-year payment, with potential milestones exceeding $15 billion and a total deal value over $15.5 billion. The source says the deal sets a record for the highest potential total value of a China ADC out-licensing transaction. When Roche licensed Hansoh's CDH17 ADC HS-20110 a year ago, the upfront payment was $80 million; this upfront payment rose sharply.